ArticlePediatric blood & cancer2024
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
Kristy L Pilbeam et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.